Cargando…

Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS—Method Development, Validation, and Application

BACKGROUND: Direct oral anticoagulants (DOACs) are prescribed for anticoagulation in patients with atrial fibrillation and venous thromboembolic disease. Fixed doses are recommended, but measuring their serum drug concentrations as a basis for dose adjustments may be useful in some clinical settings...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindahl, Sofia, Dyrkorn, Roar, Spigset, Olav, Hegstad, Solfrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Drug Monitoring 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959258/ https://www.ncbi.nlm.nih.gov/pubmed/29578938 http://dx.doi.org/10.1097/FTD.0000000000000509

Ejemplares similares

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)

Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC–QTOF–MS
por: Gundersen, Per Ole M., et al.
Publicado: (2018)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Stability of 21 Antihypertensive Drugs in Serum Collected in Standard (Nongel) Serum Tubes Versus Tubes Containing a Gel Separator
por: Hegstad, Solfrid, et al.
Publicado: (2020)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Serum or Plasma for Quantification of Direct Oral Anticoagulants?
por: Aakerøy, Rachel, et al.
Publicado: (2022)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Comparison of Two Methods, UHPLC-UV and UHPLC-MS/MS, for the Quantification of Polyphenols in Cider Apple Juices
por: Verdu, Cindy F., et al.
Publicado: (2013)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Florfenicol and Florfenicol Amine Quantification in Bull Serum and Seminal Plasma by a Single Validated UHPLC-MS/MS Method
por: Bardhi, Anisa, et al.
Publicado: (2023)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
por: Rutherford, Ole-Christian W, et al.
Publicado: (2020)

Association between low body weight and cytochrome P‐450 enzyme activity in patients with anorexia nervosa
por: Sandvik, Pål, et al.
Publicado: (2020)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study
por: Avci, Sema, et al.
Publicado: (2021)

Academic detailing as a method to improve general practitioners’ drug prescribing in type 2 diabetes: evaluation of changes in prescribing
por: Langaas, Harald Christian, et al.
Publicado: (2023)

Development and Validation of a Reliable UHPLC-MS/MS Method for Simultaneous Quantification of Macrocyclic Lactones in Bovine Plasma
por: Zeleke, Gemechu, et al.
Publicado: (2022)

Simultaneous quantification of eight hemoglobin adducts of genotoxic substances by isotope-dilution UHPLC-MS/MS
por: Gauch, Fabian, et al.
Publicado: (2022)

A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues
por: Manca, Alessandra, et al.
Publicado: (2023)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Dynamic profiling of intact glucosinolates in radish by combining UHPLC-HRMS/MS and UHPLC-QqQ-MS/MS
por: Yan, Chenghuan, et al.
Publicado: (2023)

Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study
por: Sathanantham, Vepusha, et al.
Publicado: (2022)

Simultaneous Quantification and Pharmacokinetic Study of Five Homologs of Dalbavancin in Rat Plasma Using UHPLC-MS/MS
por: Zhu, Difeng, et al.
Publicado: (2020)

A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)
por: Perrone, Alessandro, et al.
Publicado: (2021)

Serum Concentrations and Pharmacokinetics of Tranexamic Acid after Two Means of Topical Administration in Massive Weight Loss Skin-Reducing Surgery
por: Ausen, Kjersti, et al.
Publicado: (2019)

Identification and Quantification of Coumarins by UHPLC-MS in Arabidopsis thaliana Natural Populations
por: Perkowska, Izabela, et al.
Publicado: (2021)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vdm24kmjc9r8hjr731i1j78rfv